Most Americans are already familiar with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that Novo Nordisk ...

The results come as those drugs, like Wegovy and Ozempic, explode in popularity, leading to shortages as well as greater competition. Executives on Monday said those supply constraints were "not ...

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain ...

A clinical trial funded by Novo Nordisk found that Ozempic (semaglutide) was linked with reduced pain among patients with ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...

Spending on GLP-1s in Medicaid has followed broader industry trends, growing significantly over the past several years, according to a ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people ...

A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...